{"disease":{"id":"chronic-rhinitis","name":"chronic rhinitis"},"drugs":{"marketed":[{"drug_id":"fluticasone-furoate","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arnuity Ellipta","generic_name":"FLUTICASONE FUROATE","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":62,"revenue":"3100","mechanism":""},{"drug_id":"desonide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"budesonide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"flixotide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"flunisolide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aerospan Hfa","generic_name":"FLUNISOLIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"flunisolide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"mometasone","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"fluticasone","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"nasonex","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"triamcinolone","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06370468","title":"The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis","phase":"","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Zheng Liu ENT","has_results":false},{"nct_id":"NCT06678334","title":"Characteristic Transcriptomic, Proteomic and Metabolomic Molecular Studies of Nasal Secretions From Chronic Rhinitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03893227","title":"Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation","phase":"","overall_status":"COMPLETED","enrollment_count":756,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT03739216","title":"Registry of Subject Treated With ClariFix","phase":"","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Arrinex, Inc.","has_results":false},{"nct_id":"NCT04769596","title":"Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Neurent Medical","has_results":false},{"nct_id":"NCT04154605","title":"ClariFix Rhinitis RCT","phase":"NA","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Stryker Instruments","has_results":true},{"nct_id":"NCT06128200","title":"NEUROMARK Randomized Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Neurent Medical","has_results":false},{"nct_id":"NCT04614324","title":"A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)","phase":"NA","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Aerin Medical","has_results":true},{"nct_id":"NCT04533438","title":"RhinAer Procedure for Treatment of Chronic Rhinitis Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Aerin Medical","has_results":true},{"nct_id":"NCT06661252","title":"Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Diag-Nose Medical Pty Ltd","has_results":false},{"nct_id":"NCT06999044","title":"Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03181594","title":"Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Arrinex, Inc.","has_results":true},{"nct_id":"NCT06682676","title":"Diagnostic Efficacy of CDA Nasal Provocation Test in Patients With IR","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04375293","title":"Characterisation of the Nasal Microbiome in Patients With N-ERD","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05591989","title":"Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Neurent Medical","has_results":false},{"nct_id":"NCT04187976","title":"Eosinophils Endotypes in Chronic Airway Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03727347","title":"Posterior Nasal Nerve (PNN) Rhinitis Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Aerin Medical","has_results":true},{"nct_id":"NCT04684875","title":"Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Aerin Medical","has_results":false},{"nct_id":"NCT05324397","title":"Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY)","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Neurent Medical","has_results":false},{"nct_id":"NCT03791489","title":"Multi-Treatment PNN Modulation for Chronic Rhinitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Arrinex, Inc.","has_results":true},{"nct_id":"NCT05648565","title":"Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":true},{"nct_id":"NCT07168148","title":"Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05331222","title":"Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Jantar GmbH","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}